Pfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors.
Roche providing improved anti-Her2 bispecific antibody
Latest NewsResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
A new treatment paradigm
Sponsored PublicationsMedigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.
Pfizer CEO announces Succession
AppointmentsPfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors.
Experts discuss process intensification
BackgroundRoughly 150 life science professionals met at the 5th Biotech Days to discuss the latest progress in bioprocess intensification.
Formulation matters
OpinionBack in February 2017, CDMO Rentschler Biopharma SE and formulation specialist Leukocare AG joined forces to give biologics and biosimilar makers a competitive edge through significantly stabilised end products. European Biotechnology spoke with Leukocare’s CEO Michael Scholl about the impact of formulation on drug product performance.
Forbion closes Life Sciences VC Fund at €360m
Latest NewsLife Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m.
BIOSPAIN expanding
Latest NewsMatured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain.
Minoryx bags €21.3m Series B financing
Latest NewsBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M.
PD-1+ T cells trigger pulmonary fibrosis
Latest NewsA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Roche’s Tecentriq prolongs OS in SCLC
Latest NewsCancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.